RNS & Investor News

2021

Successful completion of pre-clinical studies

02 December 2014

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the successful completion of pre-clinical studies.

OptiBiotix contracted Nizo Food Research BV ("Nizo"), to undertake pre-clinical studies on three proprietary cholesterol lowering Lactobacillus strains that OptiBiotix has developed over the past two years. These strains have shown an ability to reduce cholesterol by between 71% and 82% in laboratory tests.

As announced on 11 November 2014, the pre-clinical studies assessed each strain's manufacturability, gastrointestinal robustness and activity against bile salts to determine the strain(s) most likely to achieve a successful outcome in human studies of OptiBiotix's first product, a capsular food supplement.

Results of the pre-clinical studies indicated that one strain of Lactobacillus showed preferential characteristics and is now being manufactured, encapsulated and packaged in preparation for human studies, which are scheduled for January 2015. The data from the results of these further studies are expected to be available by the end of Q3 2015.

Data from the pre-clinical studies also provided information which will be used to reduce the cost, timescale and development risk of future products, such as cholesterol lowering yoghurts, fruit juices, vegetable juices and cereal bars.

Nizo, which is one of the most advanced, independent contract research companies in the world, works with small corporate food and ingredient companies to develop and produce innovative products for the food and drink industry. For more information visit: www.nizo.com

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the outcome of these studies. The completion of pre-clinical studies is an important milestone in product development as it identifies which of our three strains is best suited for our first product, and is most likely to lead to a successful outcome in human studies. At OptiBiotix we believe that better science equals better health and we strive to ensure this becomes a reality."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd Tel: 020 7933 8780 or [email protected]
Anna Dunphy
Mike Wort
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2020

Successful completion of pre-clinical studies

02 December 2014

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the successful completion of pre-clinical studies.

OptiBiotix contracted Nizo Food Research BV ("Nizo"), to undertake pre-clinical studies on three proprietary cholesterol lowering Lactobacillus strains that OptiBiotix has developed over the past two years. These strains have shown an ability to reduce cholesterol by between 71% and 82% in laboratory tests.

As announced on 11 November 2014, the pre-clinical studies assessed each strain's manufacturability, gastrointestinal robustness and activity against bile salts to determine the strain(s) most likely to achieve a successful outcome in human studies of OptiBiotix's first product, a capsular food supplement.

Results of the pre-clinical studies indicated that one strain of Lactobacillus showed preferential characteristics and is now being manufactured, encapsulated and packaged in preparation for human studies, which are scheduled for January 2015. The data from the results of these further studies are expected to be available by the end of Q3 2015.

Data from the pre-clinical studies also provided information which will be used to reduce the cost, timescale and development risk of future products, such as cholesterol lowering yoghurts, fruit juices, vegetable juices and cereal bars.

Nizo, which is one of the most advanced, independent contract research companies in the world, works with small corporate food and ingredient companies to develop and produce innovative products for the food and drink industry. For more information visit: www.nizo.com

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the outcome of these studies. The completion of pre-clinical studies is an important milestone in product development as it identifies which of our three strains is best suited for our first product, and is most likely to lead to a successful outcome in human studies. At OptiBiotix we believe that better science equals better health and we strive to ensure this becomes a reality."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd Tel: 020 7933 8780 or [email protected]
Anna Dunphy
Mike Wort
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2019

Successful completion of pre-clinical studies

02 December 2014

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the successful completion of pre-clinical studies.

OptiBiotix contracted Nizo Food Research BV ("Nizo"), to undertake pre-clinical studies on three proprietary cholesterol lowering Lactobacillus strains that OptiBiotix has developed over the past two years. These strains have shown an ability to reduce cholesterol by between 71% and 82% in laboratory tests.

As announced on 11 November 2014, the pre-clinical studies assessed each strain's manufacturability, gastrointestinal robustness and activity against bile salts to determine the strain(s) most likely to achieve a successful outcome in human studies of OptiBiotix's first product, a capsular food supplement.

Results of the pre-clinical studies indicated that one strain of Lactobacillus showed preferential characteristics and is now being manufactured, encapsulated and packaged in preparation for human studies, which are scheduled for January 2015. The data from the results of these further studies are expected to be available by the end of Q3 2015.

Data from the pre-clinical studies also provided information which will be used to reduce the cost, timescale and development risk of future products, such as cholesterol lowering yoghurts, fruit juices, vegetable juices and cereal bars.

Nizo, which is one of the most advanced, independent contract research companies in the world, works with small corporate food and ingredient companies to develop and produce innovative products for the food and drink industry. For more information visit: www.nizo.com

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the outcome of these studies. The completion of pre-clinical studies is an important milestone in product development as it identifies which of our three strains is best suited for our first product, and is most likely to lead to a successful outcome in human studies. At OptiBiotix we believe that better science equals better health and we strive to ensure this becomes a reality."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd Tel: 020 7933 8780 or [email protected]
Anna Dunphy
Mike Wort
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2018

Successful completion of pre-clinical studies

02 December 2014

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the successful completion of pre-clinical studies.

OptiBiotix contracted Nizo Food Research BV ("Nizo"), to undertake pre-clinical studies on three proprietary cholesterol lowering Lactobacillus strains that OptiBiotix has developed over the past two years. These strains have shown an ability to reduce cholesterol by between 71% and 82% in laboratory tests.

As announced on 11 November 2014, the pre-clinical studies assessed each strain's manufacturability, gastrointestinal robustness and activity against bile salts to determine the strain(s) most likely to achieve a successful outcome in human studies of OptiBiotix's first product, a capsular food supplement.

Results of the pre-clinical studies indicated that one strain of Lactobacillus showed preferential characteristics and is now being manufactured, encapsulated and packaged in preparation for human studies, which are scheduled for January 2015. The data from the results of these further studies are expected to be available by the end of Q3 2015.

Data from the pre-clinical studies also provided information which will be used to reduce the cost, timescale and development risk of future products, such as cholesterol lowering yoghurts, fruit juices, vegetable juices and cereal bars.

Nizo, which is one of the most advanced, independent contract research companies in the world, works with small corporate food and ingredient companies to develop and produce innovative products for the food and drink industry. For more information visit: www.nizo.com

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the outcome of these studies. The completion of pre-clinical studies is an important milestone in product development as it identifies which of our three strains is best suited for our first product, and is most likely to lead to a successful outcome in human studies. At OptiBiotix we believe that better science equals better health and we strive to ensure this becomes a reality."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd Tel: 020 7933 8780 or [email protected]
Anna Dunphy
Mike Wort
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2017

Successful completion of pre-clinical studies

02 December 2014

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the successful completion of pre-clinical studies.

OptiBiotix contracted Nizo Food Research BV ("Nizo"), to undertake pre-clinical studies on three proprietary cholesterol lowering Lactobacillus strains that OptiBiotix has developed over the past two years. These strains have shown an ability to reduce cholesterol by between 71% and 82% in laboratory tests.

As announced on 11 November 2014, the pre-clinical studies assessed each strain's manufacturability, gastrointestinal robustness and activity against bile salts to determine the strain(s) most likely to achieve a successful outcome in human studies of OptiBiotix's first product, a capsular food supplement.

Results of the pre-clinical studies indicated that one strain of Lactobacillus showed preferential characteristics and is now being manufactured, encapsulated and packaged in preparation for human studies, which are scheduled for January 2015. The data from the results of these further studies are expected to be available by the end of Q3 2015.

Data from the pre-clinical studies also provided information which will be used to reduce the cost, timescale and development risk of future products, such as cholesterol lowering yoghurts, fruit juices, vegetable juices and cereal bars.

Nizo, which is one of the most advanced, independent contract research companies in the world, works with small corporate food and ingredient companies to develop and produce innovative products for the food and drink industry. For more information visit: www.nizo.com

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the outcome of these studies. The completion of pre-clinical studies is an important milestone in product development as it identifies which of our three strains is best suited for our first product, and is most likely to lead to a successful outcome in human studies. At OptiBiotix we believe that better science equals better health and we strive to ensure this becomes a reality."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd Tel: 020 7933 8780 or [email protected]
Anna Dunphy
Mike Wort
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2016

Successful completion of pre-clinical studies

02 December 2014

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the successful completion of pre-clinical studies.

OptiBiotix contracted Nizo Food Research BV ("Nizo"), to undertake pre-clinical studies on three proprietary cholesterol lowering Lactobacillus strains that OptiBiotix has developed over the past two years. These strains have shown an ability to reduce cholesterol by between 71% and 82% in laboratory tests.

As announced on 11 November 2014, the pre-clinical studies assessed each strain's manufacturability, gastrointestinal robustness and activity against bile salts to determine the strain(s) most likely to achieve a successful outcome in human studies of OptiBiotix's first product, a capsular food supplement.

Results of the pre-clinical studies indicated that one strain of Lactobacillus showed preferential characteristics and is now being manufactured, encapsulated and packaged in preparation for human studies, which are scheduled for January 2015. The data from the results of these further studies are expected to be available by the end of Q3 2015.

Data from the pre-clinical studies also provided information which will be used to reduce the cost, timescale and development risk of future products, such as cholesterol lowering yoghurts, fruit juices, vegetable juices and cereal bars.

Nizo, which is one of the most advanced, independent contract research companies in the world, works with small corporate food and ingredient companies to develop and produce innovative products for the food and drink industry. For more information visit: www.nizo.com

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the outcome of these studies. The completion of pre-clinical studies is an important milestone in product development as it identifies which of our three strains is best suited for our first product, and is most likely to lead to a successful outcome in human studies. At OptiBiotix we believe that better science equals better health and we strive to ensure this becomes a reality."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd Tel: 020 7933 8780 or [email protected]
Anna Dunphy
Mike Wort
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2015

Successful completion of pre-clinical studies

02 December 2014

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the successful completion of pre-clinical studies.

OptiBiotix contracted Nizo Food Research BV ("Nizo"), to undertake pre-clinical studies on three proprietary cholesterol lowering Lactobacillus strains that OptiBiotix has developed over the past two years. These strains have shown an ability to reduce cholesterol by between 71% and 82% in laboratory tests.

As announced on 11 November 2014, the pre-clinical studies assessed each strain's manufacturability, gastrointestinal robustness and activity against bile salts to determine the strain(s) most likely to achieve a successful outcome in human studies of OptiBiotix's first product, a capsular food supplement.

Results of the pre-clinical studies indicated that one strain of Lactobacillus showed preferential characteristics and is now being manufactured, encapsulated and packaged in preparation for human studies, which are scheduled for January 2015. The data from the results of these further studies are expected to be available by the end of Q3 2015.

Data from the pre-clinical studies also provided information which will be used to reduce the cost, timescale and development risk of future products, such as cholesterol lowering yoghurts, fruit juices, vegetable juices and cereal bars.

Nizo, which is one of the most advanced, independent contract research companies in the world, works with small corporate food and ingredient companies to develop and produce innovative products for the food and drink industry. For more information visit: www.nizo.com

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the outcome of these studies. The completion of pre-clinical studies is an important milestone in product development as it identifies which of our three strains is best suited for our first product, and is most likely to lead to a successful outcome in human studies. At OptiBiotix we believe that better science equals better health and we strive to ensure this becomes a reality."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd Tel: 020 7933 8780 or [email protected]
Anna Dunphy
Mike Wort
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2014

Successful completion of pre-clinical studies

02 December 2014

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the successful completion of pre-clinical studies.

OptiBiotix contracted Nizo Food Research BV ("Nizo"), to undertake pre-clinical studies on three proprietary cholesterol lowering Lactobacillus strains that OptiBiotix has developed over the past two years. These strains have shown an ability to reduce cholesterol by between 71% and 82% in laboratory tests.

As announced on 11 November 2014, the pre-clinical studies assessed each strain's manufacturability, gastrointestinal robustness and activity against bile salts to determine the strain(s) most likely to achieve a successful outcome in human studies of OptiBiotix's first product, a capsular food supplement.

Results of the pre-clinical studies indicated that one strain of Lactobacillus showed preferential characteristics and is now being manufactured, encapsulated and packaged in preparation for human studies, which are scheduled for January 2015. The data from the results of these further studies are expected to be available by the end of Q3 2015.

Data from the pre-clinical studies also provided information which will be used to reduce the cost, timescale and development risk of future products, such as cholesterol lowering yoghurts, fruit juices, vegetable juices and cereal bars.

Nizo, which is one of the most advanced, independent contract research companies in the world, works with small corporate food and ingredient companies to develop and produce innovative products for the food and drink industry. For more information visit: www.nizo.com

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the outcome of these studies. The completion of pre-clinical studies is an important milestone in product development as it identifies which of our three strains is best suited for our first product, and is most likely to lead to a successful outcome in human studies. At OptiBiotix we believe that better science equals better health and we strive to ensure this becomes a reality."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd Tel: 020 7933 8780 or [email protected]
Anna Dunphy
Mike Wort
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

2013

Successful completion of pre-clinical studies

02 December 2014

OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces the successful completion of pre-clinical studies.

OptiBiotix contracted Nizo Food Research BV ("Nizo"), to undertake pre-clinical studies on three proprietary cholesterol lowering Lactobacillus strains that OptiBiotix has developed over the past two years. These strains have shown an ability to reduce cholesterol by between 71% and 82% in laboratory tests.

As announced on 11 November 2014, the pre-clinical studies assessed each strain's manufacturability, gastrointestinal robustness and activity against bile salts to determine the strain(s) most likely to achieve a successful outcome in human studies of OptiBiotix's first product, a capsular food supplement.

Results of the pre-clinical studies indicated that one strain of Lactobacillus showed preferential characteristics and is now being manufactured, encapsulated and packaged in preparation for human studies, which are scheduled for January 2015. The data from the results of these further studies are expected to be available by the end of Q3 2015.

Data from the pre-clinical studies also provided information which will be used to reduce the cost, timescale and development risk of future products, such as cholesterol lowering yoghurts, fruit juices, vegetable juices and cereal bars.

Nizo, which is one of the most advanced, independent contract research companies in the world, works with small corporate food and ingredient companies to develop and produce innovative products for the food and drink industry. For more information visit: www.nizo.com

Stephen O'Hara, CEO of OptiBiotix, commented: "We are extremely pleased with the outcome of these studies. The completion of pre-clinical studies is an important milestone in product development as it identifies which of our three strains is best suited for our first product, and is most likely to lead to a successful outcome in human studies. At OptiBiotix we believe that better science equals better health and we strive to ensure this becomes a reality."

 

For further information, please contact:

OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
www.optibiotix.com
Contact via Walbrook below
Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
Tel: 020 7148 7900
Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
Tel: 020 7469 0936
Walbrook PR Ltd Tel: 020 7933 8780 or [email protected]
Anna Dunphy
Mike Wort
Mob: 07876 741 001
Mob: 07900 608 002

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.